Literature DB >> 10454718

Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease.

M A Tarnopolsky1, G Parise.   

Abstract

Several neuromuscular disorders are associated with reductions in intramuscular adenosine triphosphate (ATP) and/or phosphocreatine (PCr). These alterations have been primarily characterized using (31)P-magnetic resonance spectroscopy ((31)P-MRS). We prospectively measured total creatine, PCr, and ATP in muscle biopsies from 81 patients: normal controls (n = 33), mitochondrial cytopathy (n = 8), neuropathic (n = 3), dystrophy/congenital myopathies (n = 7), inflammatory myopathy (n = 12), and miscellaneous myopathies (n = 18) using direct biochemical analysis. Intramuscular concentrations of PCr and ATP were lower for the dystrophy/congenital myopathy, inflammatory myopathy, and mitochondrial disease patients with ragged red fiber (RRF) as compared with normal controls (P < 0.05). Total creatine was lower for the dystrophy/congenital myopathy group as compared with the normal control group (P < 0.05). These values compare favorably to results from other studies using (31)P-MRS and provide external validation for the values obtained using that method. Given the reductions in high-energy phosphate compounds in these patients, there is the potential for therapeutic intervention with creatine monohydrate supplementation. Copyright 1999 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454718     DOI: 10.1002/(sici)1097-4598(199909)22:9<1228::aid-mus9>3.0.co;2-6

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  39 in total

Review 1.  Chronic progressive external ophthalmoplegia.

Authors:  Andrew G Lee; Paul W Brazis
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 2.  Cardiac spectroscopy: techniques, indications and clinical results.

Authors:  Meinrad Beer
Journal:  Eur Radiol       Date:  2004-03-06       Impact factor: 5.315

3.  31P-MRS of skeletal muscle is not a sensitive diagnostic test for mitochondrial myopathy.

Authors:  Tina Dysgaard Jeppesen; Bjørn Quistorff; Flemming Wibrand; John Vissing
Journal:  J Neurol       Date:  2007-02-04       Impact factor: 4.849

Review 4.  Physical activity for paediatric rheumatic diseases: standing up against old paradigms.

Authors:  Bruno Gualano; Eloisa Bonfa; Rosa M R Pereira; Clovis A Silva
Journal:  Nat Rev Rheumatol       Date:  2017-05-23       Impact factor: 20.543

Review 5.  The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options.

Authors:  Fernando Scaglia; Jennifer L Northrop
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans.

Authors:  M A Tarnopolsky; G Parise; M J Gibala; T E Graham; J W Rush
Journal:  J Physiol       Date:  2001-06-15       Impact factor: 5.182

Review 7.  The clinical laboratory evaluation of the patient with noninflammatory myopathy.

Authors:  R L Wortmann; G D Vladutiu
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

8.  Perfusion has no effect on the in vivo CEST effect from Cr (CrCEST) in skeletal muscle.

Authors:  Feliks Kogan; Randall B Stafford; Erin K Englund; Garry E Gold; Hari Hariharan; John A Detre; Ravinder Reddy
Journal:  NMR Biomed       Date:  2016-11-29       Impact factor: 4.044

9.  A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells.

Authors:  Oded Shaham; Nancy G Slate; Olga Goldberger; Qiuwei Xu; Arvind Ramanathan; Amanda L Souza; Clary B Clish; Katherine B Sims; Vamsi K Mootha
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-08       Impact factor: 11.205

Review 10.  Drug treatment for facioscapulohumeral muscular dystrophy.

Authors:  M R Rose; R Tawil
Journal:  Cochrane Database Syst Rev       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.